These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28490259)

  • 1. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
    Paulden M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
    [No Abstract]   [Full Text] [Related]  

  • 2. Some inconsistencies in NICE's consideration of social values.
    Paulden M; O'Mahony JF; Culyer AJ; McCabe C
    Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
    Hale G; Morris J; Barker-Yip J
    J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence-based decision-making 3: Health technology assessment.
    O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
    Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA.
    Goldman D; Lakdawalla D; Philipson TJ; Yin W
    Health Econ; 2010 Oct; 19(10):1109-16. PubMed ID: 20842680
    [No Abstract]   [Full Text] [Related]  

  • 9. Why it's Time to Abandon the ICER.
    Paulden M
    Pharmacoeconomics; 2020 Aug; 38(8):781-784. PubMed ID: 32390066
    [No Abstract]   [Full Text] [Related]  

  • 10. Modifying NICE's Approach to Equity Weighting.
    Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
    Charlton V
    Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation in medical information technology: why the numbers don't add up.
    Eisenstein EL; Ortiz M; Anstrom KJ; Crosslin DR; Lobach DF
    AMIA Annu Symp Proc; 2006; 2006():914. PubMed ID: 17238533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 14. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
    Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J
    Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Searching for a threshold - Not so NICE..
    Mooney G; Coast J; Jan S; ; Ryan M; Wiseman V
    J Health Serv Res Policy; 2007 Jul; 12(3):190; author reply 190-1. PubMed ID: 17716427
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessing the added value of health technologies: reconciling different perspectives.
    Drummond M; Tarricone R; Torbica A
    Value Health; 2013; 16(1 Suppl):S7-13. PubMed ID: 23317646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction.
    Phillips KA
    Value Health; 2017 Jan; 20(1):30-31. PubMed ID: 28212965
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The National Institute for Health and Clinical Excellence Single Technology Appraisal process: lessons from the first 4 years.
    Kaltenthaler E; Papaioannou D; Boland A; Dickson R
    Value Health; 2011 Dec; 14(8):1158-65. PubMed ID: 22152188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.